Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 3 · 60%High 1 · 20%

Anti‐VEGF vs steroids

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 330 participants
High

Anti‐VEGF vs laser

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with BRVO

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 473 participants
Moderate

Anti‐VEGF vs sham

Visual acuity · macular oedema secondary to branch retinal vein occlusion

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Anti‐VEGF vs control

Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2508 participants
Moderate